• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 30, 2013

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Researchers from the University of Texas at Austin have identified epigenetic changes that contribute to the development of alcohol tolerance. Drinking alcohol changes the expressions of many different genes, most of whom are presumably not specifically related to tolerance. Read More

Pharma: Other news to note

Otsuka Pharmaceutical Co. Ltd., of Tokyo, said the European Medicines Agency has accepted the submission of a marketing authorization application for the potential approval of tolvaptan for the treatment of autosomal dominant polycystic kidney disease. Read More

Stock Movers

Read More

Other news to note

Alkermes plc, of Dublin, said the FDA has scheduled a meeting of the Allergenic Products Advisory Committee on Jan. 28, 2014, to discuss its biologics license application (BLA) for the ragweed sublingual allergy immunotherapy tablet. Read More

Microbiome knowledge gets more complex and more interesting

One of 2013’s scientific breakthroughs of the year, according to Science, was the human microbiome. “Research on the trillions of bacterial cells that call the human body home made it clear how much these microbes do for us,” the American Association for the Advancement of Science announced, adding that “‘Personalized’ medicine will need to take these microbial tenants into account in order to be effective.” Read More

Doug Richards trades biotech for best sellers

As a biotech business development executive turned best-selling author, Doug Richards has been compared to Michael Crichton for penning novels that straddle the line between suspense and science fiction with a biomedical twist. Read More

Seeking innovation, J&J extends reach to life science start-ups

LONDON – Johnson & Johnson has ratcheted the pharma’s quest for innovation up yet another notch, establishing a network of five partnering offices at life sciences clusters across the UK to work with the London center it set up earlier this year to scout for technology across Europe. Read More

Renamed Adheron cements focus on Cadherin-11 asset

Back in 2006, a company named Synovex Corp. was launched around discoveries by scientists Michael Brenner and David Lee into the role of Cadherin-11 as an adhesive control part of cell-cell interaction. And for several years, the fully virtual discovery firm operated under the radar until a lead clinical asset emerged: an antibody designed to inhibit Cad-11 designated SDP051. Read More

BioWorld’s top 10 most impactful biopharma news, trends and breakthroughs for 2013

In the world of biopharmaceuticals, there’s no such thing as a boring year. Yet even by those standards, 2013 may be a standout, as the sector saw explosive growth on the capital markets, witnessed burgeoning scientific advances reach maturation and encountered new regulatory challenges that will set the stage in the years to come. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe